

## Both $\alpha$ and $\beta$ chains of HLA-DC class II histocompatibility antigens display extensive polymorphism in their amino-terminal domains

Lena Schenning, Dan Larhammar\*, Per Bill, Klas Wiman<sup>2</sup>, Ann-Kristin Jonsson, Lars Rask<sup>1</sup> and Per A. Peterson

Department of Cell Research, The Wallenberg Laboratory, University of Uppsala, and <sup>1</sup>Swedish University for Agricultural Sciences, Box 562, S-751 22 Uppsala, Sweden

<sup>2</sup>Present address: Memorial Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10021, USA

\*To whom reprint requests should be sent

Communicated by P.A. Peterson

**At least three class II antigens, all composed of an  $\alpha$  and a  $\beta$  subunit, are encoded in the human major histocompatibility complex, i.e., DR, DC and SB. Two cDNA clones, encoding a DC $\alpha$  and a DC $\beta$  chain, respectively, were isolated from a cDNA library of the lymphoblastoid cell line Raji (DR3,w6). The two polypeptides predicted from the nucleotide sequences of these clones are each composed of a signal peptide, two extracellular domains, a hydrophobic transmembrane region and a short cytoplasmic tail. Comparison of the DC $\alpha$  sequence with two previously published partial sequences shows that the majority of the differences is located in the amino-terminal domain. The differences are not randomly distributed; a cluster of replacements is present in the central portion of the amino-terminal domain. Likewise, the allelic polymorphism of the DC $\beta$  chains occurs preferentially in the amino-terminal domain, where three minor clusters of replacements can be discerned. The non-random distribution of the variability of DC $\alpha$  and  $\beta$  chains may be due to phenotypic selection against replacement substitutions in the second domains of the polypeptides.**

**Key words:** cDNA/class II antigens/HLA/MHC/polymorphism

### Introduction

The class II antigens of the major histocompatibility complex (MHC) are expressed on B lymphocytes, macrophages and activated T lymphocytes (Thorsby, 1977; Evans *et al.*, 1978) and participate in interactions between different cell types of the immune system (Benacerraf, 1981). They are dimers composed of an  $\alpha$  chain of ~34 000 daltons non-covalently associated with a  $\beta$  chain of ~28 000 daltons (Klareskog *et al.*, 1977). Three distinct class II antigens have been identified in man, denoted DR, DC and SB (Klareskog *et al.* 1977; Tosi *et al.*, 1978; Shaw *et al.*, 1980). Two additional class II heterodimers have recently been described; BR and FA (Tanigaki and Tosi, 1982; Watson *et al.*, 1983).

cDNA clones sequenced in our and other laboratories have provided the complete primary structures of DR $\alpha$  and  $\beta$  chains (Larhammar *et al.*, 1982a; Lee *et al.*, 1982; Long *et al.*, 1983; Gustafsson *et al.*, in preparation). Both subunits are composed of two extracellular domains of similar size, a membrane-spanning hydrophobic segment, and a short cytoplasmic tail. The DC subunits are similarly organized (Larhammar *et al.*, 1982b; Auffray *et al.*, 1982). The exten-

sive homologies between the different class II antigens suggest that they have evolved from a common ancestor through processes involving gene duplications.

A remarkable feature of the class II histocompatibility antigens is their extensive polymorphism. The exact role of the polymorphism is as yet unknown, as is the mechanism of action of the class II antigens. The polymorphism of the DR antigens is almost exclusively limited to the  $\beta$  chain (Charron and McDevitt, 1979; Silver and Ferrone, 1979; Gustafsson *et al.*, in preparation). Less is known about the polymorphism of the DC antigens. In contrast to the DR $\alpha$  chain, evidence from genomic hybridizations and partial DC $\alpha$  sequences (Auffray *et al.*, 1982, 1983; Götz *et al.*, 1983) suggest that the DC $\alpha$  chain is polymorphic, as is the DC $\beta$  chain (Larhammar *et al.*, 1982b, 1983b; Böhme *et al.*, 1983; Wake *et al.*, 1982). This dual polymorphism of the DC chains may be a reflection of a function distinct from that of the DR chains.

Apart from their obvious importance in a number of immunological functions, the class II antigens of the MHC serve as an excellent model system for the analysis of genetic polymorphism at the DNA level. Thus, by determining a large number of sequences, it may eventually be possible to gain insight into the mechanisms generating the polymorphism. To this end, we describe here the complete sequences of two cDNA clones encoding HLA-DC antigen chains.

### Results

#### *Isolation and characterization of DC cDNA clones*

Two cDNA libraries were made from Raji cell mRNA (Wiman *et al.*, 1982). The library enriched for DR $\alpha$  mRNA by size fractionation was screened with a fragment from a DC $\alpha$  cDNA clone (Auffray *et al.*, 1982) as probe. Out of ~10 000 clones, 38 reacted with the probe. A clone denoted pII- $\alpha$ -5, containing a long insert, was chosen for further characterization. Its nucleotide sequence was determined as shown in Figure 1. The nucleotide sequence and the deduced amino acid sequence are shown in Figure 2.

The library enriched for  $\beta$ -chain mRNA was screened with a fragment from the DC $\beta$  cDNA clone pII- $\beta$ -1 (Larhammar *et al.*, 1982b) as probe. Out of 20 000 clones, 90 reacted with the probe. A clone denoted pII- $\beta$ -2 was chosen for further characterization since its restriction map showed similarities to that of pII- $\beta$ -1, yet displayed unique features. The clone pII- $\beta$ -2 was sequenced as described in Figure 1. The nucleotide sequence and the translated amino acid sequence are shown in Figure 4.

*DC $\alpha$  nucleotide sequence and predicted amino acid sequence*  
Ten nucleotides precede the AUG initiation codon in the DC $\alpha$  clone (see Figure 2). The first 23 amino acids constitute the signal peptide. Like most other signal sequences (von Heijne, 1983), the DC $\alpha$  signal sequence has a core of hydrophobic amino acids, and residues with small side chains at positions -3 (Cys) and -1 (Gly). The processed DC $\alpha$  chain

consists of 231 amino acids, 193 of which constitute the extracellular part. The DC $\alpha$  chain predicted from pII- $\alpha$ -5 is one amino acid shorter than that predicted from pDCH1 (Auffray *et al.*, 1982) and that described by Götz *et al.* (1983) due to a deletion at position 56 (Figure 5). A stretch of 23 mainly hydrophobic residues comprises the trans-membrane region, and 15 residues reside on the cytoplasmic side of the plasma membrane. Three cysteines are present in the extracellular part. Those at positions 109 and 165 are conserved in DC $\alpha$  and DR $\alpha$  chains (Auffray *et al.*, 1982; Larhammar *et al.*, 1982a; Götz *et al.*, 1983) as well as in their murine homologues (Benoist *et al.*, 1983; Hyldig-Nielsen *et al.*, 1983; Mathis *et al.*, 1983), and form an intradomain disulfide bond. The cysteine at position 47 of the pII- $\alpha$ -5 DC $\alpha$  chain is not found in the other DC $\alpha$  chains. It is located in what appears

to be a highly polymorphic region (see Figure 5). A cysteine is also present at position 11 in the DC $\alpha$  sequence reported by Götz *et al.* (1983). Like the DR $\alpha$  chain and the murine  $\alpha$  chains, the DC $\alpha$  chains have a cysteine in the trans-membrane region (position 197). Since this residue is conserved in all  $\alpha$  chains known, it may have a specific function like serving as the attachment site for fatty acid. The attachment sites for N-linked carbohydrate at positions 80 and 120 are also conserved in all human and murine  $\alpha$  chains known to date.

The 3'-untranslated region of pII- $\alpha$ -5 encompasses ~500 bp, whereas that of pDCH1 consists of only 130 bp. Comparison with a DC $\alpha$  gene (A.-K. Jonsson, unpublished data) shows that part of the difference between the two cDNA clones can be accounted for by differential splicing of the intron separating the two exons encoding the 3'-untranslated region (Figure 3). The mRNA transcribed from the gene encoding pII- $\alpha$ -5 has retained ~210 bp of the intron preceding the last exon of the gene encoding pDCH1 (see Figure 2). Hybridization with a DC $\alpha$  restriction fragment to mRNA isolated from Raji cells, the heterozygous cell line that served as the source of the cDNA libraries, reveals two distinct mRNA species (data not shown). However, no cDNA clone representing the shorter DC $\alpha$  mRNA species has been found in the Raji library. A reasonable explanation for this negative result is the fact that the cDNA library used was constructed from mRNA enriched by size fractionation for DR $\alpha$  message, which is several hundred nucleotides longer than the shorter DC $\alpha$  mRNA species. Whether the intron segment retained in pII- $\alpha$ -5 is a unique feature of one of the Raji alleles or will occur also in other allelic products remains to be seen.

The polyadenylation signal AATAAA (Proudfoot and Brownlee, 1976) found in pDCH1 corresponds to AACAAA in pII- $\alpha$ -5, which is consistent with the presence of ~160 additional nucleotides at the 3' end of pII- $\alpha$ -5, as compared with pDCH1. The aberrant polyadenylation signal of pII- $\alpha$ -5 apparently does not prevent transport of the mRNA from the nucleus to the cytoplasm, probably because correct poly(A)




Fig. 1. Restriction maps of the HLA-DC cDNA clones pII- $\alpha$ -5 and pII- $\beta$ -2. Coding parts of the inserts are indicated by filled boxes. Arrows show sequences determined by the chemical degradation procedure after labelling at 5' ends (fine arrows) or 3' ends (bold arrows).

-23	Met Ile Leu Asn Lys Ala Leu Met Leu Gly Ala Leu Ala Leu Thr Thr Val Met Ser Pro Cys Gly	-1 +1	Gly Glu Asp Ile Val	4
TGGGAAGAGG	ATG ATC CTA AAC AAA GCT CTG ATG CTG GGG GCC CTT GCC CTG ACC ACC GTG ATG AGC CCC TGT GGA GGT GAA GAC ATT GTG			91
Ala Asp His Val Ala Ser Tyr Gly Val Asn Leu Tyr Gln Ser Tyr Gly Pro Ser Gly Gln Tyr Thr His Glu Phe Asp Gly Asp Glu Gln	GCT GAC CAC GTC GCC TCT TAT GGT GTA AAC TTG TAC CAG TCT TAC GGT CCC TCT GGC CAG TAC ACC CAT GAA TTT GAT GGA GAT GAG CAG			34 181
Phe Tyr Val Asp Leu Gly Arg Lys Glu Thr Val Trp Cys Leu Pro Val Leu Arg Gln Phe Arg Phe Asp Pro Gln Phe Ala Leu Thr Asn	TTC TAC GTG GAC CTG GGG AGG AAG GAG ACT GTG TGT TGG TGT CCT GTT CTC AGA CAA TTT AGA TTT GAC CCG CAA TTT GCA CTG ACA AAC			64 271
Ile Ala Val Leu Lys His Asn Leu Asn Ser Leu Ile Lys Arg Ser	ATC GCT GTC CTA AAA CAT AAC TTG AAC AGT CTG ATT AAA CGC TCC	Asn Ser Thr	Ala Ala Thr Asn Glu Val Pro Glu Val Thr Val Phe	94 361
Ser Lys Ser Pro Val Thr Leu Gly Gln Pro Asn Ile Leu Ile	TCC AAG TCT CCC GTG ACA CTG GGT CAG CCC AAC ATC CTC ATC	Cys TGT	Leu Val Asp Asn Ile Phe Pro Pro Val Val Asn Ile Thr Trp Leu	124 451
Ser Asn Gly His Ser Val Thr Glu Gly Val Ser Glu Thr Ser Phe Leu Ser Lys Ser Asp His Ser Phe Phe Lys Ile Ser Tyr Leu Thr	AGC AAT GGG CAC TCA GTC ACA GAA GGT GTT TCT GAG ACC AGC TTC CTC TCC AAG AGT GAT CAT TCC TTC TTC AAG ATC AGT TAC CTC ACC			154 541
Leu Leu Pro Ser Ala Glu Glu Ser Tyr Asp	CTC CTC CCT TCT GCT GAG GAG AGT TAT GAC	Cys TGC	Lys Val Glu His Trp Gly Leu Asp Lys Pro Leu Leu Lys His Trp Glu Pro Glu Ile	184 631
Pro Ala Pro Met Ser Glu Leu Thr Glu Thr Val Val Cys Ala Leu Gly Leu Ser Val Gly Leu Val Gly Ile Val Val Gly Thr Val Phe	CCA GCC CCT ATG TCA GAG CTC ACA GAG ACT GTG GTC TGC GCC CTG GGA TTG TCT GTG GGC CTC GTG GGC ATT GTG GTG GGC ACT GTC TTC			214 721
Ile Ile Arg Gly Leu Arg Ser Val Gly Ala Ser Arg His Gln Gly Pro Leu ***	ATC ATC CGA GGC CTG CGT TCA GGT GCT TCC AGA CAC CAA GGG CCC TTG TGA		ATCCCATCCTGGAATGGAAGGTGCATCGCCATCTACAGGACGAGAAGA	231 823
GTGGACTTGCTACATGACCTAGCATTATTTCTGGCCCAATTTATCATATCCCTTTTCTCCTCCAAATGTTTCTCCTCTCACCTCTTCTGTGGGACTTAAATTTGCTATATCTGCTCAGAG				943
CTCACAATGCGCTTTGAATTTATTTCCCTGACTTCCCTGATTTTTTCTTCTTAAGTGTACCTACTAAGAGTTGCTGGAGTAAGCCACCCAGCTACCTAATTCCTCAGTAACTCCATCT				1063
ATAATCTCCATGGAAGC	TCCCTTTATGAGATATATGCAAAATTTTCCATCTTTTCATCXAGGGCTGACTGAAACCGTGCTAAGAATTTGGGAGACTCTCTTGTTTCAAGCCAA			1183
TTTAACATCAITTACCAGATCATTTGTCTATGTCAGTAACACAGAAGCAACCAACTACAGTATAGCTGATAACATGA				1261

Fig. 2. Nucleotide sequence and predicted amino acid sequence of the DC $\alpha$  cDNA clone pII- $\alpha$ -5. Cysteines involved in the intramolecular disulfide bond and the attachment sites for N-linked carbohydrates are within boxes, as is the aberrant polyadenylation signal. Arrows mark exon boundaries. The splice junction utilized in the gene encoding pDCH1 is indicated by the arrow within parentheses.

signals are present further downstream in the DC $\alpha$  gene (see Figure 3). Like most cDNA clones isolated from the two Raji libraries, pII- $\alpha$ -5 may be truncated at the 3' end.

#### DC $\beta$ nucleotide sequence and predicted amino acid sequence

The insert of pII- $\beta$ -2 starts at a position corresponding to amino acid -21 in the signal peptide (see Figure 4). (The signal sequence of the only DC $\beta$  chain whose sequence is complete is 32 amino acids long; Larhammar *et al.*, 1983b.) The processed DC $\beta$  chain encoded by pII- $\beta$ -2 displays the characteristic features of other human and murine class II  $\beta$  chains (Larhammar *et al.*, 1982b, 1983a, 1983b; Kratzin *et al.*, 1981; Long *et al.*, 1983; Choi *et al.*, 1983; Malissen *et al.*, 1983; Saito *et al.*, 1983; Gustafsson *et al.*, in preparation). Four cysteines are present in the extracellular part, forming two intradomain disulfide loops. A single site is available for attachment of N-linked carbohydrate at position 19. The hydrophobic trans-membrane region encompasses 21 amino acids. The intra-cytoplasmic segment is shorter than those of DR $\beta$  and murine  $\beta$  chains due to a splice junction mutation causing a separate cytoplasmic 'exon' encoding eight amino acids to be non-expressed (Hyldig-Nielsen *et al.*, 1984). The 3'-untranslated region of pII- $\beta$ -2 ends prematurely 90 bp




Fig. 3. Schematic representation of the differential splicing occurring in the 3' part of DC $\alpha$  genes. The additional nucleotide stretches found in pII- $\alpha$ -5, as compared with pDCH1 (Auffray *et al.*, 1982), are indicated by the hatched boxes. Arrows mark polyadenylation signals in the DC $\alpha$  gene encoded by cosII-102 (A.-K. Jonsson, unpublished data). Abbreviations used: CP, connecting peptide; M, membrane-spanning segment; C, cytoplasmic stretch; 3'UT, 3'-untranslated region.




Fig. 4. Nucleotide sequence and predicted amino acid sequence of the DC $\beta$  cDNA clone pII- $\beta$ -2. Cysteines and the attachment site for N-linked carbohydrate are within boxes. Arrows mark exon boundaries inferred from a DC $\beta$  gene (Larhammar *et al.*, 1983b).

upstream of the polyadenylation signals (cf. pII- $\beta$ -1; Larhammar *et al.*, 1982b).

#### Discussion

Southern blot hybridizations suggest that the human genome contains two DC $\alpha$ -related and two DC $\beta$ -related genes (Böhme *et al.*, 1983; Auffray *et al.*, 1983; Wake *et al.*, 1982). One DC $\alpha$ -related and one DC $\beta$ -related gene appear virtually non-polymorphic as judged from the positions of several restriction enzyme sites. In contrast, alleles of the other DC $\alpha$  and DC $\beta$  gene show extensive restriction site polymorphism. It is not known whether both DC $\alpha$ -related and both DC $\beta$ -related genes are expressed. The three DC $\beta$  clones discussed here (Figure 6) display extensive homology to each other in the 3'-untranslated region. Since the invariant DC $\beta$ -related gene does not cross-hybridize to the 3'-untranslated region of these clones (G. Andersson, unpublished data), we conclude that the three DC $\beta$  clones correspond to allelic products. In contrast, we cannot formally prove that the DC $\alpha$  sequences (Figure 5) are derived from true alleles. However, pII- $\alpha$ -5 and pDCH1 display >90% homology in their 3'-untranslated regions, why we provisionally consider them as allelic products.

The polymorphism of the DR antigens is known to reside primarily in the  $\beta$  chains (Charron and McDevitt, 1979; Silver and Ferrone, 1979). Indeed, in the DR $\alpha$  chain, only a single variant position has been found although DR $\alpha$  sequences from six different sources have been described (Larhammar *et al.*, 1982a; Korman *et al.*, 1982a, 1982b; Lee *et al.*, 1982; Yang *et al.*, 1982; Das *et al.*, 1983). In contrast, the  $\alpha$  chains of the DC antigens display extensive polymorphism (Figure 5). Although the two previously published DC $\alpha$  sequences are incomplete, corresponding to 85% and 53% of the polypeptide chains, respectively (Auffray *et al.*, 1982; Götz *et al.*, 1983), alignment of these sequences with the DC $\alpha$  sequence reported here conclusively shows that most of the polymorphism is expressed in the amino-terminal domain (residues 1-86, see Figure 5). Among the residues available for comparison, the amino-terminal domain of the DC $\alpha$  chain encoded by pII- $\alpha$ -5 displays 10 and 16 differences, respectively, to the correspon-




Fig. 5. Comparison of DC $\alpha$  amino acid sequences. The pII- $\alpha$ -5 sequence is derived from a cDNA clone of the DR3,w6 cell line Raji, and pDCH1 is from a cDNA clone of a DR4,w6 cell line (Auffray *et al.*, 1982). DC1 $\alpha$  is a protein sequence from a DR2,2 cell line (Götz *et al.*, 1983). Stars denote amino acid residues not available for comparison. Arrows mark exon boundaries. Sites for addition of N-linked carbohydrate and the membrane-spanning segment are within boxes.




Fig. 6. Comparison of DC $\beta$  amino acid sequences. The pII- $\beta$ -2 and pII- $\beta$ -1 sequences are derived from cDNA clones of the DR3,w6 cell line Raji (Larhammar *et al.*, 1982b) and cosII-102 from a gene of a DR4,4 individual (Larhammar *et al.*, 1983b). DC1 $\beta$  is a protein sequence of a DR2,2 cell line (Götz *et al.*, 1983). Stars denote amino acid residues not available for comparison. Arrows mark exon boundaries. The site for addition of N-linked carbohydrate and the membrane-spanning segment are within boxes.

ding parts of pDCH1 and DC1 $\alpha$ . The second domain (residues 87–180), on the other hand, shows only five and four differences, respectively. A similarly uneven distribution of the allelic polymorphism has also been found in the  $\alpha$  chain of the murine structural homologue of DC $\alpha$ , i.e., I-A $\alpha$  (Benoist *et al.*, 1983). The amino acid replacements are scattered over the entire amino-terminal domain in both DC $\alpha$  and I-A $\alpha$ . However, a cluster of differences can be discerned in both polypeptides around amino acid 50. At only four of the positions available for comparison do all three DC $\alpha$  chains display unique amino acids (Figure 5; positions 47, 50, 53 and 174). Three of these positions occur in the cluster of variable residues. Although many of the replacements involve amino acids with similar chemical properties, some non-conservative exchanges also occur, e.g., at the positions where all three DC $\alpha$  chains are unique. Interestingly, at all four of these positions, the DR $\alpha$  sequence displays one of the variant amino acids.

The second DC $\alpha$  domain, which is immunoglobulin-like and comparatively constant, shows higher homology to the invariant DR $\alpha$  chain (~65%) than does the amino-terminal domain (~45% homology). The trans-membrane regions of the two types of  $\alpha$  chains are more homologous (almost 80%) than the extracellular portions. Likewise, the  $\beta$  chains of DC and DR show less homology in the amino-terminal domains (~60%; residues 1–94), than in the second domains (~70%; residues 95–188). Again, the trans-membrane regions are well conserved, displaying ~80% homology, most

likely due to a conservative pressure acting to maintain hydrophobicity. Also, these regions are well conserved within each allelic series. Possibly, the second domains and trans-membrane domains are crucial in the interaction between  $\alpha$  and  $\beta$  chains of the different dimers, and have therefore been allowed to diverge less. Conversely, the differences between the various types of  $\alpha$  and  $\beta$  chains, respectively, may have to be large enough to prevent formation of hybrid antigens, e.g., DC $\alpha$ DR $\beta$ .

Within the DC $\beta$  allelic series, the polymorphism in the amino-terminal domain is even more pronounced than in the DC $\alpha$  chains (see Figure 6). As in the DC $\alpha$  chains, amino acid replacements are found along the entire DC $\beta$  amino-terminal domain. However, three minor clusters of relatively more variability can be found (positions 52–57, 70–77, and 84–90). At no position do all four DC $\beta$  chains have unique amino acids. However, three different amino acid residues occur at seven positions, six of which are located in the amino-terminal domain. As in the DC $\alpha$  chains, several amino acid replacements involve residues with markedly different properties. At six of the seven positions where three different amino acids occur, at least one of the amino acid residues is also found in DR $\beta$  chains at the corresponding position (Gustafsson *et al.*, in preparation). This, together with the evidence from the DC $\alpha$  comparison, may indicate that although the conservative selection pressure appears to be low in the amino-terminal domains (see below), at a certain polymorphic position only a limited repertoire of amino acids is

compatible with the overall structure of the polypeptide.

The mechanism for the generation of the genetic polymorphism of the MHC antigens is far from understood. The preferential location of amino acid replacements in the amino-terminal domains of the class II antigen chains may suggest that substitutions are introduced by a process different from that generating substitutions in the second domains. However, Gustafsson *et al.* (in preparation) have demonstrated that the numbers of silent substitutions are virtually identical in the amino-terminal and the second domains of both DR and DC $\beta$  chains. This observation indicates that the exons of the two domains accumulate mutations at a common basic mutation rate. The numbers of replacement substitutions in the first domains were found to be in accordance with this mutation rate, suggesting that the conservative selection pressure on amino acid replacements is low in these parts of the polypeptide chains. In contrast, the numbers of replacement substitutions in the second domains are significantly lower than expected from the numbers of silent substitutions, implying that severe constraints act on replacement substitutions in this region. Unfortunately, a statistical evaluation of the DC $\alpha$  polymorphism is not possible since only one DC $\alpha$  nucleotide sequence has been published previously. Moreover, that sequence is incomplete. In fact, comparison of the pII- $\alpha$ -5 and pDCH1 sequences indicates a higher basic mutation rate in the first DC $\alpha$  domain than in the second domain. Additional sequence information is required to allow conclusions to be drawn.

The non-random distribution of the amino acid replacements in the first and second domains of DC $\alpha$  and  $\beta$  chains may suggest that events related to gene conversion (Efstratiadis *et al.*, 1980; Weiss *et al.*, 1983) may contribute to the polymorphism. In keeping with this notion is the observation that the sequences of cosII-102 and DC1 $\beta$  are identical at positions 71–77, yet differ extensively at positions 84–90 (see Figure 6). Here, instead, cosII-102 is identical to pII- $\beta$ -1 (also at the nucleotide level). Thus, in the two regions mentioned, cosII-102 displays sequences suggesting that this DC $\beta$  gene is a hybrid between DC1 $\beta$  and pII- $\beta$ -1. Such cross-wise similarities have also been observed between different class I histocompatibility antigens (Weiss *et al.*, 1983). Whether the polymorphism has arisen due to point mutations or gene conversion events (or both), fixation seems to be due to selection at the phenotypic level. As in antibody chains (Baltimore, 1981), certain regions of the  $\alpha$  and  $\beta$  chains seem to be more amenable to amino acid replacements than other regions. Whether this propensity affects both structural and functional aspects of the class II antigens remains to be seen.

Since both DC subunits are polymorphic, the DC antigen may display more extensive polymorphism than DR, whose  $\alpha$  subunit is virtually invariant. However, the polymorphic DC $\alpha$  and DC $\beta$  genes are located < 15 kb apart in the MHC (Bo Serenius, unpublished data), so few recombination events would be expected to occur between the two genes. The DC $\alpha$  gene may therefore co-evolve with a linked DC $\beta$  gene to an extent which disallows heterodimer formation between the DC $\alpha$  chain and DC $\beta$  chains of non-linked alleles (trans-gene complementation). Thus, the number of different functional DC antigens may not necessarily be the product of the numbers of  $\alpha$  and  $\beta$  alleles. However, the conservation of the second domains and membrane regions of the  $\alpha$  and  $\beta$  chains may ascertain heterodimer formation between products of non-linked alleles.

## Materials and methods

### Construction and screening of cDNA libraries

Isolation of mRNA from the lymphoblastoid cell line Raji (DR3,w6) and cDNA synthesis after size fractionation of mRNA have been described (Wiman *et al.*, 1982). The cDNA library enriched for DR $\alpha$  clones was screened by colony hybridization (Maniatis *et al.*, 1982) with the nick-translated (Rigby *et al.*, 1977) 583-bp *Rsa*I-*Stu*I fragment containing most of the coding part of the DC $\alpha$  cDNA clone pDCH1 (Auffray *et al.*, 1982). The cDNA library enriched for  $\beta$ -chain clones was screened (Gergen *et al.*, 1979) with the 627-bp *Ava*I fragment covering almost the entire coding part of the DC $\beta$  cDNA clone pII- $\beta$ -1 (previously denoted pDR- $\beta$ -1; Larhammar *et al.*, 1982b).

### Nucleotide sequence determination

Nucleotide sequences were determined by the chemical degradation procedure (Maxam and Gilbert, 1980). Two sequencing errors have been corrected in the DC $\beta$  sequence of pII- $\beta$ -1 (previously denoted pDR- $\beta$ -1; Larhammar *et al.*, 1982b), both involving *Bst*NI sites, whose second Cs are methylated in the *Escherichia coli* strain used and therefore behave aberrantly in the chemical degradation reactions. Position 499 should be a C and position 853 should be a C. Neither of these corrections influences the deduced amino acid sequence of pII- $\beta$ -1.

## Acknowledgements

We are grateful to Ms. Anita Moren for skilful technical assistance and Ms. Elisabetta Rossi for help with computer analyses. We thank Drs. C. Auffray and J.L. Strominger for the DC $\alpha$  probe. This work was supported by grants from the Swedish Cancer Society, Marcus Borgström's Fund, and King Gustav V's 80-years' Fund.

## References

- Auffray, C., Korman, A.J., Roux-Dosseto, M., Bono, R. and Strominger, J.L. (1982) *Proc. Natl. Acad. Sci. USA*, **79**, 6337-6341.
- Auffray, C., Ben-Nun, A., Roux-Dosseto, M., Germain, R.N., Seidman, J.G. and Strominger, J.L. (1983) *EMBO J.*, **2**, 121-124.
- Baltimore, D. (1981) *Cell*, **26**, 295-296.
- Benacerraf, B. (1981) *Science (Wash.)*, **212**, 1229-1238.
- Benoist, C.O., Mathis, D.J., Kanter, M.R., Williams, V.E., II and McDevitt, H.O. (1983) *Cell*, **34**, 169-177.
- Böhme, J., Owerbach, D., Denaro, M., Lernmark, A., Peterson, P.A. and Rask, L. (1983) *Nature*, **301**, 82-84.
- Charron, D.J. and McDevitt, H.O. (1979) *Proc. Natl. Acad. Sci. USA*, **76**, 6567-6571.
- Choi, E., McIntyre, K., Germain, R.N. and Seidman, J.G. (1983) *Science (Wash.)*, **221**, 283-286.
- Das, H.K., Lawrence, S.K. and Weissman, S.M. (1983) *Proc. Natl. Acad. Sci. USA*, **80**, 3543-3547.
- Efstratiadis, A., Posakony, J.W., Maniatis, T., Lawn, R.M., O'Connell, C., Spritz, R.A., DeRiel, J.K., Forget, B.G., Weissman, S.M., Slightom, J.L., Blechl, A.E., Smithies, O., Baralle, F.E., Shoulders, C.C. and Proudfoot, N.J. (1980) *Cell*, **21**, 653-668.
- Evans, R.L., Faldetta, T.J., Humphreys, R.E., Pratt, D.M., Yunis, E.J. and Schlossman, S.F. (1978) *J. Exp. Med.*, **148**, 1440-1445.
- Gergen, J.P., Stern, R.H. and Wensink, P.C. (1979) *Nucleic Acids Res.*, **7**, 2115-2136.
- Götz, H., Kratzin, H., Thinnies, F.P., Yang, C.-y., Kruse, T., Pauly, E., Köbel, S., Egert, G., Wernet, P. and Hilschmann, N. (1983) *Hoppe-Seyler's Z. Physiol. Chem.*, **364**, 749-755.
- Hyldig-Nielsen, J.J., Schenning, L., Hammerling, U., Widmark, E., Heldin, E., Lind, P., Serenius, B., Lund, T., Flavell, R.A., Lee, J.S., Trowsdale, J., Schreier, P., Sablitzky, F., Larhammar, D., Peterson, P.A. and Rask, L. (1983) *Nucleic Acids Res.*, **11**, 5055-5071.
- Hyldig-Nielsen, J.J., Larhammar, D., Serenius, B., Andersson, G., Rask, L. and Peterson, P.A. (1984) *Nature*, in press.
- Klareskog, L., Sandberg-Trägårdh, L., Rask, L., Lindblom, J.B., Curman, B. and Peterson, P.A. (1977) *Nature*, **265**, 248-251.
- Korman, A.J., Auffray, C., Schamboeck, A. and Strominger, J.L. (1982a) *Proc. Natl. Acad. Sci. USA*, **79**, 6013-6017.
- Korman, A.J., Knudsen, P.J., Kaufman, J.F. and Strominger, J.L. (1982b) *Proc. Natl. Acad. Sci. USA*, **79**, 1844-1848.
- Kratzin, H., Yang, C.-y., Götz, H., Pauly, E., Köbel, S., Egert, G., Thinnies, F.P., Wernet, P., Altevogt, P. and Hilschmann, N. (1981) *Hoppe-Seyler's Z. Physiol. Chem.*, **362**, 1665-1669.
- Larhammar, D., Gustafsson, K., Claesson, L., Bill, P., Wiman, K., Schenning, L., Sundelin, J., Widmark, E., Peterson, P.A. and Rask, L. (1982a) *Cell*, **30**, 153-161.

- Larhammar,D., Schenning,L., Gustafsson,K., Wiman,K., Claesson,L., Rask,L. and Peterson,P.A. (1982b) *Proc. Natl. Acad. Sci. USA*, **79**, 3687-3691.
- Larhammar,D., Hammerling,U., Denaro,M., Lund,T., Flavell,R.A., Rask,L. and Peterson,P.A. (1983a) *Cell*, **34**, 179-188.
- Larhammar,D., Hyldig-Nielsen,J.J., Servenius,B., Andersson,G., Rask,L. and Peterson,P.A. (1983b) *Proc. Natl. Acad. Sci. USA*, **80**, 7313-7317.
- Lee,J.S., Trowsdale,J., Travers,P.J., Carey,J., Grosveld,F., Jenkins,J. and Bodmer,W.F. (1982) *Nature*, **299**, 750-752.
- Long,E.O., Wake,C.T., Gorski,J. and Mach,B. (1983) *EMBO J.*, **2**, 389-394.
- Malissen,M., Hunkapiller,T. and Hood,L. (1983) *Science (Wash.)*, **221**, 750-754.
- Maniatis,T., Fritsch,E.F. and Sambrook,J. (1982) *Molecular Cloning*, published by Cold Spring Harbor Laboratory Press, NY, pp. 387-389.
- Mathis,D.J., Benoist,C.O., Williams,V.E.,II, Kanter,M.R. and McDevitt,H.O. (1983) *Cell*, **32**, 745-754.
- Maxam,A.M. and Gilbert,W. (1980) *Methods Enzymol.*, **65**, 499-560.
- Rigby,P.W.J., Dieckmann,M., Rhoades,C. and Berg,P. (1977) *J. Mol. Biol.*, **113**, 237-251.
- Saito,H., Maki,R.A., Clayton,L. and Tonegawa,S. (1983) *Proc. Natl. Acad. Sci. USA*, **80**, 5520-5524.
- Shaw,S., Johnson,A.H. and Shearer,G.M. (1980) *J. Exp. Med.*, **152**, 565-580.
- Silver,J. and Ferrone,S. (1979) *Nature*, **279**, 436-437.
- Tanigaki,N. and Tosi,R. (1982) *Immunol. Rev.*, **66**, 5-37.
- Thorsby,E. (1977) *Transplant. Proc.*, **9**, 393-400.
- Tosi,R., Tanigaki,N., Centis,D., Ferrara,G.B. and Pressman,D. (1978) *J. Exp. Med.*, **148**, 1592-1611.
- von Heijne,G. (1983) *Eur. J. Biochem.*, **133**, 17-21.
- Wake,C.T., Long,E.O. and Mach,B. (1982) *Nature*, **300**, 372-374.
- Watson,A.J., DeMars,R., Trowbridge,I.S. and Bach,F.H. (1983) *Nature*, **304**, 358-361.
- Weiss,E., Golden,L., Zakut,R., Mellor,A., Fahrner,K., Kvist,S. and Flavell,R.A. (1983) *EMBO J.*, **2**, 453-462.
- Wiman,K., Larhammar,D., Claesson,L., Gustafsson,K., Schenning,L., Bill,P., Böhme,J., Denaro,M., Dobberstein,B., Hammerling,U., Kvist,S., Servenius,B., Sundelin,J., Peterson,P.A. and Rask,L. (1982) *Proc. Natl. Acad. Sci. USA*, **79**, 1703-1707.
- Yang,C.-y., Kratzin,H.J., Götz,H., Thinnis,F.P., Kruse,T., Egert,G., Pauly,E., Kölbl,S., Wernet,P. and Hilschmann,N. (1982) *Hopper-Seyler's Z. Physiol. Chem.*, **363**, 671-676.

Received on 14 November 1983